VTGN icon

VistaGen Therapeutics
VTGN

Overview Fund Activity

14 hedge funds and large institutions have $2.3M invested in VistaGen Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
DADC
1
D.A. Davidson & Co
Montana
$184K
2
UBS Group
2
UBS Group
Switzerland
$11K
3
TRCT
3
Tower Research Capital (TRC)
New York
$1K

Top Sellers

1
SM
1
Sabby Management
Florida
$48K
2
Vanguard Group
2
Vanguard Group
Pennsylvania
$69K
Name Market Value Shares Shares
Change 		Shares
Change %
SFM
1
Sphera Funds Management
Israel
$1.02M 544,100 – –
Parallax Volatility Advisers
2
Parallax Volatility Advisers
California
$516K 275,848 – –
NC
3
Nexthera Capital
New York
$258K 138,132 – –
DADC
4
D.A. Davidson & Co
Montana
$184K 98,500 +7,500 +8%
LTFS
5
Ladenburg Thalmann Financial Services
Florida
$84K 45,076 – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$69K 37,027 -2,132 -5%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$56K 30,097 – –
SM
8
Sabby Management
Florida
$48K 25,537 -147,942 -85%
HighTower Advisors
9
HighTower Advisors
Illinois
$38K 20,215 – –
Northern Trust
10
Northern Trust
Illinois
$20K 10,918 – –
UBS Group
11
UBS Group
Switzerland
$11K 6,087 +6,087 New
HFM
12
Hartford Financial Management
Connecticut
$2K 1,300 – –
TRCT
13
Tower Research Capital (TRC)
New York
$1K 579 +579 New
AIM
14
Acrospire Investment Management
Illinois
– – -100 Closed
PCP
15
Proficio Capital Partners
Massachusetts
$0 89 +89 New